Search

Displaying results 3401 - 3410 of 7186 in total
  1. Drug

    Letrozole

    go.drugbank.com/drugs/DB01006
    ApprovedInvestigational

    Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990. It is a third generation aromatase inhibitor like exemestane and anastrozole, meaning it does not significantly affe...

    Mixtures: Kisqali Femara Co-pack, Kisqali Femara Co-packProducts: Co Letrozole
  2. Drug

    Pembrolizumab

    go.drugbank.com/drugs/DB09037
    ApprovedInvestigational

    [F136] It was developed by Merck & Co and first approved for the treatment of metastatic malignant melanoma by the FDA on September 4, 2014,[L2954] becoming the first approved therapy against PD-1. … [L38934,L43257] In September 2025, the US FDA approved a formulation of pembrolizumab that includes [berahyaluronidase alfa] (Keytruda QLEX) to allow for subcutaneous administration.[L54026]

  3. Drug

    Carbamide peroxide

    go.drugbank.com/drugs/DB11129
    ApprovedInvestigational

    Some adverse effects of carbamide peroxide as a dental bleaching agent include dentin sensitivity and/or gingival irritation led by unstable and reactive H+ free radicals and low pH from prolonged use. … The FDA considers carbamide peroxide to be safe in oral mucosal injury drug products as an oral wound healing agent, although there is insufficient data to establish general recognition of the effectiveness

  4. Drug

    rdESAT-6

    go.drugbank.com/drugs/DB21906
    Approved

    rdESAT-6 is a recombinant dimer of Mycobacterium tuberculosis early secretory antigenic target used as an ingredient in the diagnostic agent SIILTIBCY along with rCFP-10.

  5. Drug

    Carboplatin

    go.drugbank.com/drugs/DB00958
    ApprovedInvestigational

    Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with ...

  6. Drug

    Taurochenodeoxycholic acid

    go.drugbank.com/drugs/DB08833
    Experimental

    As a medication, taurochenodeoxycholic acid reduces cholesterol formation in the liver, and is likely used as a choleretic to increase the volume of bile secretion from the liver and as a cholagogue to … Its physiologic function is to emulsify lipids such as cholesterol in the bile.

  7. Drug

    Oxaprozin

    go.drugbank.com/drugs/DB00991
    Approved

    Oxaprozin is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis.

  8. Drug

    Sulfanilamide

    go.drugbank.com/drugs/DB00259
    ApprovedWithdrawn

    Sulfanilamide is a molecule containing the sulfonamide functional group attached to an aniline.

  9. Drug

    Adenosine phosphate

    go.drugbank.com/drugs/DB00131
    ApprovedInvestigationalNutraceuticalWithdrawn

    Adenosine phosphate, or adenylic acid, is an adenine nucleotide containing one phosphate group esterified to the sugar moiety in the 2'-, 3'-, or 5'-position. … Adenosine phosphate was withdrawn by the FDA since it was considered neither safe nor effective for its intended uses as a vasodilator and an anti-inflammatory.[L43937]

    Synonyms: 5'-O-Phosphonoadenosine
  10. Drug

    Retifanlimab

    go.drugbank.com/drugs/DB15766
    ApprovedInvestigational

    By blocking the PD-1/PD-L1/2 pathway, retifanlimab potentiates T-cell activity and boosts the immune response against cancer cells. … Retifanlimab is a humanized IgG4 kappa monoclonal antibody that binds to the programmed death receptor-1 (PD-1), blocking PD-1 interaction with its ligands, programmed death-ligand 1 (PD-L1) and programmed